These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36330954)

  • 21. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
    Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
    J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
    Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.
    Gierisch ME; Pedot G; Walser F; Lopez-Garcia LA; Jaaks P; Niggli FK; Schäfer BW
    Sci Rep; 2019 Jan; 9(1):951. PubMed ID: 30700749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells.
    El Beaino M; Liu J; Wasylishen AR; Pourebrahim R; Migut A; Bessellieu BJ; Huang K; Lin PP
    BMC Cancer; 2020 Jan; 20(1):3. PubMed ID: 31898537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma.
    Wei E; Mitanoska A; O'Brien Q; Porter K; Molina M; Ahsan H; Jung U; Mills L; Kyba M; Bosnakovski D
    Mol Cancer; 2024 Oct; 23(1):222. PubMed ID: 39367409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
    Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
    J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
    Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O
    Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
    Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
    PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.
    Erkizan HV; Scher LJ; Gamble SE; Barber-Rotenberg JS; Sajwan KP; Üren A; Toretsky JA
    Cell Cycle; 2011 Oct; 10(19):3397-408. PubMed ID: 21926473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
    Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
    Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
    McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
    Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.
    García-Domínguez DJ; Hajji N; Sánchez-Molina S; Figuerola-Bou E; de Pablos RM; Espinosa-Oliva AM; Andrés-León E; Terrón-Camero LC; Flores-Campos R; Pascual-Pasto G; Robles MJ; Machado I; Llombart-Bosch A; Magagnoli G; Scotlandi K; Carcaboso ÁM; Mora J; de Álava E; Hontecillas-Prieto L
    Oncogene; 2021 Sep; 40(39):5843-5853. PubMed ID: 34345016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
    Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
    Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
    Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
    Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex.
    Mo J; Tan K; Dong Y; Lu W; Liu F; Mei Y; Huang H; Zhao K; Lv Z; Ye Y; Tang Y
    Oncogene; 2023 Jan; 42(1):11-25. PubMed ID: 36357572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.
    Tanner JM; Bensard C; Wei P; Krah NM; Schell JC; Gardiner J; Schiffman J; Lessnick SL; Rutter J
    Mol Cancer Res; 2017 Nov; 15(11):1517-1530. PubMed ID: 28720588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
    Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
    Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
    Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
    Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.